As we age, some cells stop dividing but do not disappear. These are known as senescent cells.
Senescent cells are not simply inactive. They can release inflammatory molecules and other signals that affect surrounding tissues. Their accumulation is considered one of the biological processes associated with aging and age-related disease.
This has led to a new therapeutic idea: what if we could selectively remove these cells?
Medicines designed to do this are known as senolytics.
What Are Senescent Cells?
Cellular senescence is a natural biological response. A cell may enter a senescent state after DNA damage, cellular stress or repeated division.
In some situations, this is beneficial. Senescence can prevent damaged cells from continuing to divide and plays roles in processes such as wound healing.
The problem may arise when senescent cells accumulate and are not efficiently cleared by the immune system.
These cells can release a mixture of inflammatory and signaling molecules that may contribute to chronic inflammation and tissue dysfunction.
What Are Senolytics?
Senolytics are compounds designed to selectively eliminate senescent cells while leaving healthy cells relatively unaffected.
Another group, called senomorphics, takes a different approach. Instead of killing senescent cells, these compounds aim to reduce their harmful inflammatory and signaling activity.
Both strategies are being investigated as potential ways to target cellular senescence rather than treating individual age-related diseases separately.
What Have Animal Studies Shown?
Animal research has produced some of the strongest evidence supporting the senolytic concept.
In experimental models, reducing the burden of senescent cells has improved several measures of tissue function and age-related disease. Some studies have also reported improvements in physical function and lifespan.
These findings provide important evidence that cellular senescence is not simply a marker of aging. It may contribute directly to some age-related deterioration.
But successful experiments in animals do not establish that senolytics will produce the same benefits in humans.
What Do We Know in Humans?
Early human studies of several senolytic approaches have begun, including trials in specific age-related diseases and conditions.
The results are scientifically interesting, but the evidence remains preliminary.
We do not yet have large, definitive clinical trials demonstrating that senolytic treatment slows biological aging, prevents multiple age-related diseases or extends healthy lifespan in humans.
This distinction is particularly important because senescent cells also have useful biological functions. Removing them safely may require careful selection of the target, dose, timing and patient population.
Are Senolytics Anti-Aging Medicines?
Not yet.
Senolytics represent one of the most direct attempts to target a recognized biological mechanism of aging.
That makes them scientifically important.
But a compelling mechanism is not the same as a proven treatment.
Before senolytics can become part of evidence-based longevity medicine, clinical trials must demonstrate that they provide meaningful benefits to people without creating unacceptable risks.
